BACKGROUND: Dysmenorrhea is a common risk factor for chronic pain conditions including bladder pain syndrome. Few studies have formally evaluated asymptomatic bladder pain sensitivity in dysmenorrhea, and whether this largely reflects excess pelvic symptom reporting due to comorbid psychological dysfunction. OBJECTIVE: We sought to determine whether bladder hypersensitivity is more common among women reporting moderate or greater dysmenorrhea, without chronic pain elsewhere, after accounting for anxiety and depression. Demonstrating this would suggest that dysmenorrhea might be an early clue for visceral or widespread pain hypersensitivity and improve understanding of potential precursors to bladder pain syndrome. STUDY DESIGN: We compared cohorts of regularly menstruating women, without symptoms of chronic pain elsewhere, reporting (1) moderate-to-severe dysmenorrhea (n ¼ 98) and (2) low levels or no menstrual pain (n ¼ 35). Participants underwent rapid bladder filling following a standard water ingestion protocol, serially rating bladder pain and relative urgency during subsequent distension. Potential differences in bladder volumes were controlled for by sonographic measurement at standard cystometric thresholds. Bladder sensitivity was also measured with complementary measures at other times separately including a simplified rapid filling test, palpation of the bladder wall, and through ambulatory self-report. Anxiety and depression were evaluated with the National Institutes of Health Patient-Reported Outcomes Measurement Information System measures.
Introduction
Over a third of reproductive-age women report moderate-to-severe levels of cyclical menstrual pain.
1,2 Dysmenorrhea is also a risk factor for developing other pain disorders, including endometriosis-associated pelvic pain, bladder pain syndrome (BPS), or irritable bowel syndrome. 3e5 Notably, central sensory processing abnormalities observed in many chronic pelvic pain states may also be found in episodic dysmenorrhea. 6e8 A focused investigation into gynecological risk factors for BPS is particularly of high value, as it more commonly affects women, 9 and current treatments, such as pentosan polysulfate, 10 amitriptyline, 11 or cystoscopic hydrodistension, 12 are only modestly effective. The limited efficacy of these treatments reflects the multifactorial mechanisms underlying BPS, particularly in later stages, which may include cross-organ sensitization, central nervous system sensitization, mucosal inflammation, and neuropsychological factors. 13 Identifying an early clinical marker for BPS such as visceral hypersensitivity would be valuable for determining future risk and developing targeted treatments. One classic example is abnormally low anal manometry thresholds, present in about 60% of irritable bowel syndrome patients (about 10-fold higher than healthy controls). 14 Although women with dysmenorrhea appear to have lower anal manometry thresholds, 15 this measure is not used in practice to assess risk. A noninvasive test would be more feasible for large-scale longitudinal clinical studies. We previously have found that noninvasive bladder filling, provoked by oral water ingestion and monitored with sonographic bladder volume measurement, is perceived as painful at lower levels of distention among certain dysmenorrhea patients. 16 Measures are stable when repeated a month later, closely resembling results in patients with classic BPS. 16, 17 One underlying hypothesis for this finding is that repetitive episodes of dysmenorrhea promote cross-organ or central sensitization. This is supported by clinical observations 18 and experimentally in animal models of provoked 19 However, limitations of prior patient-based assessments include retrospective study designs and inconsistent measurement of menstrual pain. Furthermore, many patients with visceral sensitivity also have comorbid histories of anxiety and depression, known to influence bladder symptom reporting. 20 Assessment for such features was not built into our initial bladder provocation validation study, nor did we include clinical exams to account for structural causes of secondary dysmenorrhea.
In this follow-up study we had 2 primary objectives. We tested the hypothesis that women with moderate or higher dysmenorrhea will have enhanced experimental bladder sensitivity, even after adjusting for potential differences in anxiety or depression. Secondly, we measured the construct validity of this bladder sensitivity phenotype by comparing formal bladder provocation pain with other measures including home symptom monitoring and physical examebased testing.
Materials and Methods

Participants and recruitment
The study was approved by the NorthShore University HealthSystem Institutional Review Board and informed consent was obtained before participation. This prospective observational study was designed to characterize uterine cross-organ influences on bladder pain, recruiting female participants (ages 18e45 years) with fliers posted in the community, through contact via the Illinois Women's Health Registry, and by referral from gynecology clinics. Potential participants were instructed to complete a telephone screen. Eligible participants were scheduled for an initial screening visit.
Inclusion criteria
Healthy controls were required to rate their average pain 2 on a 0e10 numerical rating scale (NRS) (0: no pain, 10: worst pain imaginable) during menses and to have no concurrent chronic pain diagnoses. Dysmenorrhea participants had to rank menses pain >4 on 0e10 NRS and have no concurrent chronic pain diagnoses. Participants with overt chronic pain conditions (eg, BPS) were also studied, but these results will be reported elsewhere.
Exclusion criteria
Participants were excluded for the presence of active pelvic or abdominal malignancies, absence of regular menses, active genitourinary infection in the last 4 weeks, inability to read or comprehend the informed consent in English, refusal to undergo pelvic examination/testing, hypertension, and refusal to withdraw from oral contraceptives for 2 months prior to the study visit.
Screening visit
Participants completed questionnaires (detailed below) encompassing medical, surgical, psychological, and gynecological history. All data were entered into REDCap with automatic field range restriction. 21 A standardized pelvic exam was performed by a gynecologist who was fellowship-trained in pelvic pain evaluation (F.F.T.) blinded to subject identity. During the pelvic exam, the midline bladder (corresponding to the trigone) was palpated along with 13 other sites transvaginally, as described in Hellman et al. 22 Participants were asked to rate the severity of pain upon routine clinical palpation on a 0e10 NRS. A simplified version of the sonographic bladder test (detailed below under "Assessment Visit" section), referred to as the "rapid bladder test," was conducted at the screening visit in participants with dysmenorrhea. Participants were asked to drink 20 oz of water (within 5 minutes) and report when they reached 2 levels of bladder urgency: first sensation (when they first felt capable of urinating) and first urge (when they would ordinarily void). At each of these time points, participants recorded their bladder urgency and bladder pain on a 10-cm 0e100 visual analog scale (VAS) (0: no pain/urgency, 100: worse pain/ urgency imaginable). Note, whereas VAS was used here to improve precision, NRS was used during other pain tasks to minimize response latency.
Ultrasonography was performed on 8 participants to follow up on potential clinical exam findings to rule out secondary causes for dysmenorrhea. Among these 8 participants, 3 participants had small pelvic cysts (<2.5 Â 3.0 cm), and 1 had subserosal and intramural leiomyomata (<2.5 Â 2.5 cm).
All participants were provided luteinizing hormone urinary assay kits (Wondfo, Willowbrook, IL) to time participation for the subsequent midluteal phase assessment visit (17e25 days after onset of menses). The severity of their menstrual and bladder pain (0e10 NRS) was confirmed using webbased daily diaries over the menstrual cycle preceding the assessment visit. Participants were asked to indicate the amount of pain in each category that they experienced over the past 24 hours, with 0 ¼ no pain and 10 ¼ the worst pain imaginable each day. The menstrual pain report from these diaries was used to confirm the dysmenorrhea status reported on the telephone screen, and all AJOG at a Glance Why was this study conducted? Dysmenorrhea is a known risk factor for chronic pain conditions including bladder pain syndrome. However, it is unknown whether dysmenorrhea affects bladder sensitivity independent of psychological effects on symptom reporting.
Key findings A subset of women with dysmenorrhea reported higher levels of bladder pain. Bladder pain was correlated with menstrual pain severity independent of anxiety or depression.
What does this add to what is known?
This adds objective evidence for comorbid bladder sensitivity in dysmenorrhea using controlled experimental bladder provocation.
ajog.org GYNECOLOGY Original Research cases were required to have at least 1 menses pain score >3.
Assessment visit
For this visit, participants were asked to avoid taking short-acting, over-thecounter analgesics, opioids, and caffeine for at least 6 hours prior to arrival. All visits were scheduled to take place during the participant's luteal phase.
The National Institutes of Health Patient-Reported Outcomes Measurement Information System (PROMIS) was used to evaluate symptoms of anxiety and depression. 23 We characterized BPS symptoms using the O'Leary-Sant Interstitial Cystitis Symptom and Problem Indices (ICSI).
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The noninvasive bladder test, a mimic of clinical retrograde cystometry, was performed on all participants. 16 After spontaneously voiding, participants were asked to drink 20 oz of water (within 5 minutes) and report when they reached 3 standard cystometric urgency thresholds: first sensation, first urge to void, and maximum capacity. 25 At baseline void and at each of these time points, the bladder volume was quantified with 3-dimensional sonographic measurements (Voluson 750, GE, Wauwatosa, WI), and participants rated their bladder pain and urgency on a 0e100 VAS on a tablet computer. 17 The average magnitude of experimental bladder pain was determined by the mean of the pain scores at first sensation, first urge, and maximum capacity.
Statistics
Analyses were performed in software (SAS, Version 9.3; SAS Institute Inc, Cary, NC). Complete data sets were obtained for all analyzed participants recruited from the start of the study (August 2014) through December 2016. After confirmation of normality, group comparisons were made with a 2-tailed Student t test with P < .05 threshold for significance. Our sample sizes were unequal since the goal of this study was to specifically characterize a subset of women with dysmenorrhea at risk for developing bladder pain. To accommodate potential effects of unequal sample sizes, we confirmed the homogeneity of variance in all analyses.
Stepwise regression was used to identify the contribution of menstrual and psychological variables to bladder capacity and pain. Hartigan dip test was used to identify multimodality that would support the hypothesis of the existence of multiple pain phenotype. 26 An a priori predefined threshold, first urge pain >15 on 0e100 VAS was chosen to define the group of women with heightened bladder sensitivity. This threshold was selected based on preliminary data from an earlier study with different participants 16 suggesting that 1.5 on 0e10 NRS is the midpoint between participants with and without heightened bladder pain sensitivity. A k-means cluster analysis 27 was performed to confirm this threshold separates participants with high and low bladder pain in the current data set, including all metrics (bladder pain, bladder palpation pain, rapid bladder test, and diary data).
Results
Participant demographics and clinical characteristics
We analyzed all data from minimal to no-pain participants (n ¼ 35) and moderate or greater dysmenorrhea participants (n ¼ 98) who had completed screen visits (Figure 1 ). There were no significant group demographic differences except that African American women were more likely to have dysmenorrhea than Asian women (Table 1 ) (P ¼ .002). We observed no differences in PROMIS depression T-scores between healthy controls (50 AE 1) and participants with dysmenorrhea (51 AE 1, P ¼ .58), or in PROMIS anxiety T-scores (healthy controls: 53 AE 1, dysmenorrhea: 55 AE 1, P ¼ .39).
Bladder sensitivity testing
During functional bladder testing, differences in bladder volume at baseline, first sensation, and first urge were not significantly different between healthy controls and participants with dysmenorrhea (Figure 2, A) . Similarly, there were no differences in sonographically measured filling rates between healthy controls and participants with dysmenorrhea at first sensation (5.6 AE 0.7 vs 5.5 AE 0.7 mL/min; P ¼ .95), first urge (6.4 AE 0.5 vs 6.3 AE 0.4 mL/min; P ¼.90), and maximum capacity (8.1 AE 0.5 vs 7.7 AE 0.3 mL/min; P ¼ .50). However, maximal capacity volume in women with dysmenorrhea was significantly lower than for healthy participants (498 AE 18 vs 619 AE 34 mL, P < .001). There was no difference in baseline pain (P ¼ .52), but as hypothesized, women with dysmenorrhea had higher VAS ratings of bladder pain at first sensation, first urge, and maximum tolerance than healthy controls (Figure 2 , B) (P values < .01).
Consistent with these results, women with dysmenorrhea exhibited significantly higher scores on the ICSI than healthy controls (Table 2) . Notably, women with dysmenorrhea were more likely to report frequent urination (P ¼ .003) and burning bladder pain (P <.001) than healthy controls. However, the average total symptom scores were <6, the discriminatory threshold described initially by O'Leary and colleagues 24 where the ICSI discriminates between healthy controls and those with BPS.
Factors underlying bladder sensitivity
Using stepwise regression, we sought to establish whether menstrual pain 
Enrollment flowchart
We telephone screened 713 participants for eligibility to enroll 171 participants. After screen visit, 38 participants were unable to complete assessment visit. contributed to bladder sensitivity and pain, independent of other factors known to influence pain report such as anxiety and depression. Since neither pain nor volume was related to race (P values > .15) or age (P values > .23), these factors were not included in the models below. Women with dysmenorrhea, irrespective of menstrual pain severity, anxiety, depression, or bladder pain, had reduced maximal bladder volume (108 AE 37 mL, R 2 ¼ 0.13, P ¼ .006) ( Table 3) . Although menstrual pain status as a dichotomous variable predicted bladder pain, severity of menstrual pain was a superior predictor (Table 4 ) (R 2 ¼ 0.10, P ¼ .008) independent of anxiety (P ¼ .21) and depression (P ¼ .21). These findings confirm that dysmenorrhea is independently associated with enhanced bladder sensitivity and pain, albeit with a low explained variance.
Mathematically, the overall low explained variance logically reflects the fact that only a subset of women with dysmenorrhea exhibit increased bladder sensitivity. Since maximum tolerance is Figure 3 ) was multimodal (P < .001) with a trough between 10 and 25 on 0e100 VAS. A k-means cluster analysis separated the participants into a lowbladder pain cluster and a highbladder pain cluster. A midpoint of 15 at first urge separated the low-bladder pain cluster and high-bladder pain cluster. Although most women with dysmenorrhea do not have significant bladder pain, 24% of dysmenorrhea participants had pain at first urge >15 on 0e100 VAS compared to only 6% of healthy controls (P ¼ .012).
To separate potential effects from concurrent early menstrual pain (although none of these women bled during the assessment test), we looked at the effect of cycle day. Bladder testing was conducted on average 20.4 AE 0.3 days after menses and the correlation between cycle day and bladder pain was not significant (r ¼ e0.11, P ¼ .28).
Longitudinal stability of bladder sensitivity
To evaluate whether bladder sensitivity is a stable phenotype in a subset of participants with primary dysmenorrhea, we compared several different modalities to measure bladder sensitivity, done serially in this study (Figure 4) . Assessment measurements were performed 1e3 months after screening measurements, with diary assessments conducted in between. Among participants with dysmenorrhea, those who had pain at first urge score >15 during the assessment visit, also had more pain at first urge during the screening visit rapid bladder test (23.0 AE 4.4) (Figure 4 ) compared to those who had first urge pain score of <15 (8.7 AE 1.6, P < .001). Similarly, participants with dysmenorrhea and bladder pain >15 had more transvaginal palpation pain of the bladder during the screening visit (P ¼ .015) (Figure 4 ) and worse maximal pain in their prospective daily diary (P < .001). Thus, a multidimensional phenotype of preclinical bladder pain sensitivity is consistently observed in 24% of women with moderate-to-severe dysmenorrhea.
Comment
In this study of regularly menstruating women, we noted an association between experimental bladder sensitivity and severity of dysmenorrhea independent of psychological factors. These results add to our current understanding of pelvic visceral pain, further providing support for a role for dysmenorrhea in either central or cross-organ sensitization. In addition, we identified that women displaying such experimentally provoked pain are more likely to endorse additional dimensions of subclinical bladder symptomatology using multimethod approaches. This further confirmation of a subphenotype of dysmenorrhea with cross-organ sensitivity validates a preclinical paradigm for exploring mechanisms of visceral hypersensitivity, without the additional Stepwise regression model for maximum bladder volume
Step 1 Estimate
Step 2
Dysmenorrhea status e104 .059
Step 3 symptom complexity observed in BPS (eg, disrupted sleep, anxiety, depression).
A key strength of our study was the use of noninvasive experimental bladder assessments while accounting for anxiety and depression. Although prior studies have suggested dysmenorrhea may be associated with bladder sensitivity, 16 ,28 they have lacked either experimental measurements or controls for psychological factors or menstrual cycle influence. We used a careful clinical assessment to limit the chance that bladder sensitivity was the result of severe endometriosis, fibroids, or other structural causes (<1% of participants having a leiomyoma). The study gynecologist (F.F.T.) conducted all exams just as he would in the clinic setting to assess for subtle signs of deep infiltrating endometriosis. Our bladder test also allows participants to fill to higher capacity and is more resistant to bias. As an example of this, one of the few studies investigating long-term repeated cystometric assessment reported stable thresholds for urgency, but at mean volumes of 50e150 mL less than our noninvasive test. 29 In contrast, our healthy control thresholds are within 50 mL of results reported in 2 separate studies using noninvasive methods. 16, 17 A limitation of this study is that precisely controlled bladder filling rates are inherently not possible with physiological filling. However, bladder filling rates were similar between the 2 groups, making it unlikely that the reduced bladder sensitivity reflects differences in stimulus presentation. These associations also may not hold later in life, as we largely tested a younger cohort of women; however, for the question of future vulnerability for BPS, early identification in this age group is of high clinical relevance. Notably, with our relatively young nulliparous cohort, representation of parous women will be needed to see if these associations hold after childbirth.
This study in addition to establishing a cross-organ or central linkage between bladder and uterine sensitivity, adds to the existing literature on bladder sensitivity. Previous bladder provocation studies relied on urethral catheterization, which has been shown to elicit false early thresholds 30 and causes significant anxiety and pain, which are normally associated with lower volumes 31 and altered urethral reflexes. 32 In fact, the discomfort evoked by catheterization and resultant psychological effects may partially explain why both animal and human urodynamic studies report associations with anxiety or depression. 33, 34 Previous studies have found participants with BPS report scores on depression and anxiety questionnaires that are on average over a SD worse than the average in healthy controls. 17, 22, 35 In our previous cystometric study comparing BPS and healthy control participants, we reported a correlation between bladder pain sensitivity, anxiety (r ¼ 0.37), and depression (r ¼ 0.42). 17 However, the comparatively low correlation between anxiety or depression and bladder sensitivity reported in the present study with dysmenorrhea and healthy control participants suggests that elevated anxiety and depression might often occur after the development of severe bladder pain, rather than vice versa.
Prior work points to potential shared mechanisms of dysmenorrhea and bladder pain that could either be local (via cross-organ sensitization, or somatovisceral convergence including latent pelvic floor trigger points) or central (central sensitization or inherent difference in central nervous system pain processing). In animal models of pain induced by uterine inflammation 19, 36 or endometriosis, 37 the bladder becomes sensitized peripherally via the hypogastric nerve pathway. Of note treatment of menstrual pain decreases urinary pain both from BPS 38 and from calculosis. 18 Treatment of dysmenorrhea using hormones also reduces widespread body pain in fibromyalgia 7 while simultaneously reducing widespread somatic TABLE 4 Stepwise regression model for average experimental bladder pain
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FIGURE 3
Distribution of participants' self-reported experimental bladder pain by dysmenorrhea status
The subset of women with dysmenorrhea reported an intensity of bladder pain that was rarely observed in healthy controls. 39 Fortunately, the window of opportunity to alter this vulnerability may be wide, as a large retrospective study from Warren and colleagues 40 found that half of those with BPS report prior urinary symptoms (including pelvic pain) even decades prior to the index event leading to a formal pain diagnosis. We currently are recruiting women with dysmenorrhea in a prospective trial to determine whether oral contraceptive treatment of menstrual pain might also reduce peripheral cross-organ contributors to bladder pain sensitivity. Logically, central neural modulators like duloxetine, which may attenuate central sensitization, 41 could also be administered preemptively to see if they prevent crossorgan bladder sensitivity.
Our study suggests there is value in studying the longitudinal course of dysmenorrhea. One in 4 women with dysmenorrhea show symptoms of enhanced bladder sensitivity unrelated to anxiety or depression. Better understanding of what cofactors present in dysmenorrhea might be indicative of emerging cross-organ or central sensitization could increase our understanding of the transition to chronic pain conditions including BPS. The long-term stability of bladder sensitivity should be confirmed in further controlled studies, especially while accounting for other potential pain-promoting experiences, such as cystitis episodes or painful coital episodes. The relationship of bladder pain to menstrual pain severity suggests it may be an important modifiable factor to investigate in long-term controlled studies.
n Comparison of bladder pain measures by dysmenorrhea and bladder sensitivity
Average level of provoked pain or self-reported pain is consistent in women with dysmenorrhea and bladder sensitivity. Provoked pain during A, rapid bladder test; B, transvaginal bladder palpation; C, maximum reported bladder pain in diary; and D, formally during assessment test is grouped by status showing mean (AESE). Women with bladder pain score >15 at first urge on formal testing also had more pain during rapid test, bladder palpation, and reported in diaries. *P < .05. 
